Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of “Buy” from Analysts

Shares of Evommune, Inc. (NYSE:EVMN) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and three have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $47.1667.

EVMN has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an “overweight” rating and set a $54.00 price objective on shares of Evommune in a research report on Wednesday, February 18th. Weiss Ratings started coverage on shares of Evommune in a research report on Tuesday, February 3rd. They issued a “sell (e)” rating for the company. Raymond James Financial initiated coverage on shares of Evommune in a report on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 price target for the company. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Finally, Oppenheimer initiated coverage on shares of Evommune in a research report on Thursday, January 22nd. They set an “outperform” rating and a $42.00 price objective for the company.

Evommune Stock Performance

Shares of NYSE:EVMN opened at $23.58 on Friday. The firm has a market cap of $849.32 million and a price-to-earnings ratio of -2.92. Evommune has a 12-month low of $13.89 and a 12-month high of $33.20. The stock’s 50 day simple moving average is $24.06.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.61).

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Evommune in the 4th quarter valued at $34,000. The Manufacturers Life Insurance Company bought a new stake in Evommune during the 4th quarter worth $179,000. XTX Topco Ltd acquired a new position in Evommune in the 4th quarter worth about $321,000. Oxford Asset Management LLP bought a new position in Evommune in the fourth quarter valued at about $335,000. Finally, State Street Corp bought a new position in Evommune in the fourth quarter valued at about $539,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.